Indication intelligence, analysis and sector perception

RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting

March 23, 2023

The cell and gene therapy sector fluctuates in revenues, collaboration, regulatory submissions and expenses, but the changes may alarm investors who prefer to see expectation and consensus stability and share pricing growth. Stock pricing rises or falls before and after an earnings announcement, depending on whether the earnings meet or fall short of expectations. To date … 28 of 35 (adding AVRO and SLDB)

RegMed Investors (RMi) Research Note: Silicon Valley Bank Group (SIVB) files for bankruptcy

March 17, 2023

“Protection for reorganization” … ?? Breaking news SVB Financial Group on Friday it filed for a court-supervised reorganization under Chapter 11 bankruptcy protection to seek buyers for its assets, days after its former unit Silicon Valley Bank was taken over by U.S. regulators. <CNBC>

RegMed investors (RMi) Research Note: the aftermarket of catching a falling knife without a cut or slash

March 13, 2023

SVB clients got a painful lesson: SVB have lulled depositors into a false sense of security – that’s well over or soon to be. Thanks to the FDI, Treasury, and Federal Reserve – if not a biotech, cell and gene therapy companies would NOT be feeding their employees.